28356129|t|The effects of probiotic and synbiotic supplementation on metabolic syndrome indices in adults at risk of type 2 diabetes: study protocol for a randomized controlled trial
28356129|a|The incidence of type 2 diabetes, cardiovascular diseases, and obesity has been rising dramatically; however, their pathogenesis is particularly intriguing. Recently, dysbiosis of the intestinal microbiota has emerged as a new candidate that may be linked to metabolic diseases. We hypothesize that selective modulation of the intestinal microbiota by probiotic or synbiotic supplementation may improve metabolic dysfunction and prevent diabetes in prediabetics. In this study, a synthesis and study of synbiotics will be carried out for the first time in Iran. In a randomized triple-blind controlled clinical trial, 120 adults with impaired glucose tolerance based on the inclusion criteria will be selected by a simple random sampling method and will be randomly allocated to 6 months of 6 g/d probiotic, synbiotic or placebo. The fecal abundance of bacteria, blood pressure, height, weight, and waist and hip circumferences will be measured at baseline and following treatment. Also, plasma lipid profiles, HbA1C, fasting plasma glucose, and insulin levels, will be measured and insulin resistance (HOMA-IR) and beta-cell function (HOMA-B) will be calculated at baseline and will be repeated at months 3, 6, 12, and 18. The data will be compared within and between groups using statistical methods. The results of this trial could contribute to the evidence-based clinical guidelines that address gut microbiota manipulation to maximize health benefits in prevention and management of metabolic syndrome in prediabetes. Iranian Registry of Clinical Trials: IRCT201511032321N2. Registered on 27 February 2016.
28356129	15	24	probiotic	T007	UMLS:C0525033
28356129	29	38	synbiotic	T168	UMLS:C2936470
28356129	39	54	supplementation	T058	UMLS:C0242296
28356129	58	76	metabolic syndrome	T038	UMLS:C0524620
28356129	106	121	type 2 diabetes	T038	UMLS:C0011860
28356129	123	137	study protocol	T170	UMLS:C1507394
28356129	144	171	randomized controlled trial	T062	UMLS:C0206035
28356129	189	204	type 2 diabetes	T038	UMLS:C0011860
28356129	206	229	cardiovascular diseases	T038	UMLS:C0007222
28356129	235	242	obesity	T038	UMLS:C0028754
28356129	288	300	pathogenesis	T038	UMLS:C0699748
28356129	317	327	intriguing	T038	UMLS:C0543488
28356129	339	348	dysbiosis	T038	UMLS:C3658208
28356129	431	449	metabolic diseases	T038	UMLS:C0025517
28356129	524	533	probiotic	T007	UMLS:C0525033
28356129	537	546	synbiotic	T168	UMLS:C2936470
28356129	547	562	supplementation	T058	UMLS:C0242296
28356129	575	596	metabolic dysfunction	T038	UMLS:C0025517
28356129	609	617	diabetes	T038	UMLS:C0011847
28356129	621	633	prediabetics	T038	UMLS:C0362046
28356129	643	648	study	T062	UMLS:C2603343
28356129	666	671	study	T062	UMLS:C2603343
28356129	675	685	synbiotics	T168	UMLS:C2936470
28356129	728	732	Iran	T082	UMLS:C0022065
28356129	739	788	randomized triple-blind controlled clinical trial	T062	UMLS:C0206035
28356129	806	832	impaired glucose tolerance	T038	UMLS:C0271650
28356129	901	916	sampling method	T170	UMLS:C0449370
28356129	969	978	probiotic	T007	UMLS:C0525033
28356129	980	989	synbiotic	T168	UMLS:C2936470
28356129	993	1000	placebo	T103	UMLS:C1696465
28356129	1006	1011	fecal	T031	UMLS:C0015733
28356129	1025	1033	bacteria	T007	UMLS:C0004611
28356129	1035	1049	blood pressure	T038	UMLS:C0005823
28356129	1071	1076	waist	T201	UMLS:C0455829
28356129	1081	1099	hip circumferences	T201	UMLS:C0562350
28356129	1143	1152	treatment	T058	UMLS:C0087111
28356129	1183	1188	HbA1C	T103	UMLS:C0019018
28356129	1190	1212	fasting plasma glucose	T058	UMLS:C0583513
28356129	1218	1225	insulin	T103	UMLS:C0021641
28356129	1255	1273	insulin resistance	T058	UMLS:C4049994
28356129	1275	1282	HOMA-IR	T058	UMLS:C4049994
28356129	1288	1306	beta-cell function	T058	UMLS:C4055385
28356129	1308	1314	HOMA-B	T058	UMLS:C4055385
28356129	1454	1473	statistical methods	T062	UMLS:C1710191
28356129	1495	1500	trial	T062	UMLS:C0206035
28356129	1525	1559	evidence-based clinical guidelines	T170	UMLS:C0282451
28356129	1588	1600	manipulation	T058	UMLS:C0087111
28356129	1632	1642	prevention	T058	UMLS:C0199176
28356129	1647	1657	management	T058	UMLS:C0376636
28356129	1661	1679	metabolic syndrome	T038	UMLS:C0524620
28356129	1683	1694	prediabetes	T038	UMLS:C0362046
28356129	1696	1712	Iranian Registry	T170	UMLS:C0034975
28356129	1716	1731	Clinical Trials	T062	UMLS:C0008976
28356129	1733	1751	IRCT201511032321N2	T170	UMLS:C0282574